Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more

Recent & Breaking News (GREY:QBIO)

FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

PR Newswire February 5, 2019

Q BioMed to Present at 2019 BIO CEO & Investor Conference

PR Newswire February 1, 2019

Q BioMed Technology Partner Mannin Research Enters Into Collaboration With McMaster University for Glaucoma Drug Candidate MAN-01

PR Newswire January 25, 2019

Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001

PR Newswire January 16, 2019

Denis Corin, CEO, of Q BioMed Inc. Provides Key Update and Outlook in a New Audio Interview with SmallCapVoice.com

GlobeNewswire January 15, 2019

Q BioMed Inc Provides Shareholder Update

PR Newswire January 8, 2019

Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

PR Newswire December 12, 2018

The Global Cancer Therapy Market is set to Grow on the Wide use of Chemotherapy

PR Newswire November 28, 2018

NextGen Skeletal Cancer Drug Therapies Aim at Combating the Rising Incidence Rate of Global Cancer

PR Newswire November 28, 2018

Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

PR Newswire November 28, 2018

Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference

PR Newswire October 26, 2018

Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

PR Newswire October 9, 2018

Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000

PR Newswire September 24, 2018

Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

PR Newswire September 17, 2018

Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

PR Newswire August 20, 2018

Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

PR Newswire July 25, 2018

Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

PR Newswire June 6, 2018

Q BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser

PR Newswire June 1, 2018

Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

PR Newswire April 5, 2018

Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

PR Newswire March 16, 2018